Latest Strategic Partnerships News

Cedar Woods Properties Limited delivered a robust FY25 with a 19% increase in net profit, underpinned by a diversified project portfolio and favourable market conditions. The company signals continued growth with a 10% NPAT guidance for FY26, supported by strong presales and strategic partnerships.

Cedar Woods Properties has reported a robust 19% rise in net profit for FY25, surpassing guidance with strong presales and strategic partnerships setting the stage for continued growth.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Asset Vision reported robust FY25 results with significant revenue and cash flow growth, achieving a debt-free status while advancing its AI-powered asset management platform.

Asset Vision Co Limited reported a 22.9% increase in revenue to $5.03 million for FY2025, alongside a widening net loss of $385,797. The company’s Annual Recurring Revenue surged 28%, supported by new contracts and product innovation.

Vital Metals has raised A$6.8 million through a strategic placement led by US-based Strategic Resources LLC to advance its Tardiff Rare Earth project in Canada, aiming to deploy innovative Dry Field Force Extraction technology that could reshape project economics and environmental impact.

Locksley Resources has partnered with Rice University to pioneer domestic antimony processing in the US, aiming to reduce reliance on foreign supply and support critical defense and energy sectors.

Desert Metals Limited has had its trading suspension lifted following the release of new drilling results from its Adzope Gold Project, reopening investor access to the stock.

Regal Partners reports a robust first half of 2025 with record net inflows and strong profit growth, underpinned by strategic expansion and a healthy balance sheet.

Genetic Signatures reported a 63% revenue increase to $15.9 million in FY25, alongside a 28% reduction in underlying losses and a strategic shift in its automated diagnostics platform development.

Livium Ltd reports a significant A$6.6 million uplift in net assets driven by a reduction in fire claim provisions, recognition of a deferred tax asset, and equity accounting of its LieNA® joint venture with Mineral Resources.

LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.